-
Pfizer to acquire Anacor Pharmaceuticals
NEW YORK — Pfizer announced Monday that it would be acquiring Anacor Pharmaceuticals for about $5.2 billion, a transaction that has been approved by both companies’ boards of directors. Currently, Anacor’s flagship asset, crisaborole — a non-steroidal topical PDE inhibitor with anti-inflammatory properties — is currently awaiting review from the Food and Drug Administration to treat mild to moderate eczema.MD Labs' Rxight advances President's Precision Medicine Initiative
WASHINGTON – In an effort to expand upon President Barack Obama’s Precision Medicine Initiative and explore innovative ways to individualize patient care, representatives from MD Labs recently met with senior leadership at the White House Office of Science and Technology Policy.